Patient-derived tumor xenograft study with CDK4/6 inhibitor plus AKT inhibitor for management of metastatic castrate resistant prostate cancer
Ontology highlight
ABSTRACT: We applied DNA content flow cytometry to a series of prostate cancer (PC) patient derived tumor xenografts (PDTXs). We interrogated purified sorted tumor fractions from each sample with whole genome copy number variant (CNV) analyses. These identified a variety of somatic genomic lesions targeting genes and cellular pathways in PC. Of significant interest are lesions that may affect responses to therapies. Guided by the genomic alterations in these models and interrelated mechanisms between androgen signaling axis, the cell cycle, and AKT pathway, we identified and investigated the combination of CDK4/6 inhibitors with AKT inhibitors as a potential therapy for patients with mCRPC. Using 3-D spheroid drug assays followed by in vivo experiments in three unique PDTX models, these preclinical results highlight the potential use of CDK4/6 inhibitor with AKT inhibitors for the treatment of mCRPC who have intact retinoblastoma pathway, thereby, providing the experimental data support and rationale for future clinical investigation
ORGANISM(S): Homo sapiens
PROVIDER: GSE230411 | GEO | 2023/05/31
REPOSITORIES: GEO
ACCESS DATA